查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197798

寡核甘酸合成市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Oligonucleotide Synthesis Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計寡核甘酸合成市場在預測期內的複合年增長率為 12.3%。

COVID-19 正在影響寡核甘酸合成市場的增長。 反過來，對 COVID-19 診斷的需求不斷增長，也增加了全球對構成分子診斷產品基礎的寡核甘酸原材料的需求。 2022 年 3 月在 PLOS One 上發表的一項研究證實，該寡核甘酸成功靶向冠狀病毒基因組中的 5'-polyU。 此外，開發具有基本突變靶點（如 5'-polyU）的 COVID-19 療法可以減少新型 SARS-CoV-2 的產生和傳播。 此類研究正在影響藥物開發中寡核甘酸的需求和採用，影響大流行期間的市場增長。

此外，多家公司正在投資寡核甘酸合成，預計這將在預測期內推動市場增長。 例如，2021 年 9 月，SpeeDx 將投資本地寡核甘酸製造，以降低供應鏈風險並開發更重要的關鍵診斷主權能力。 預計這些發展將增加寡核甘酸在藥物開發中的採用，預計將在預測期內推動市場增長。

其他重要因素包括增加政府對製藥和生物技術公司的投資和研發支出，以及合成寡核甘酸在分子診斷和臨床應用中的使用。

政府越來越多地資助各種基因組學項目，以開發治療多種慢性和罕見疾病的先進療法。 預計這將增加對用於藥物開發的寡核甘酸的需求，從而推動市場增長。 例如，2022 年 9 月，美國國立衛生研究院投資超過 6 億美元，開始下一階段的人類大腦基因組計劃。 這筆資金將幫助設計新的方法，將治療藥物和其他分子靶向特定的腦細胞群。

此外，企業和政府為促進基於寡核甘酸的藥物的開發以及寡核甘酸技術在製藥和生物技術行業的採用而採取的舉措不斷增加，預計也將推動市場增長。 例如，2021 年 2 月，CPI 在藥品製造創新中心啟動了一個項目，以徹底改變寡核甘酸的製造。 藥品製造創新中心已啟動與阿斯利康、Exactmer、諾華和英國研究與創新公司的合作，以開發可擴展、可持續和更具成本效益的寡核甘酸（合成 DNA 或 RNA 的短鏈）藥品製造過程。 這一發展有望提高這種令人興奮的新型藥物的生產能力和生存能力，從而在預測期內推動市場增長率。

此外，在分子診斷和臨床應用中越來越多地採用寡核甘酸也有助於市場增長。 例如，2022 年 2 月，伊利諾伊大學厄巴納分校的研究人員開發了一種用於癌症檢測的新型 miRNA 即時檢驗。 該測試使用納米粒子捕獲人血清中的腫瘤特異性 microRNA (miRNA)。 2021 年 1 月，Diagenode 推出了一種新的小 RNA 測序解決方案 D-Plex Small RNA DNBSEQ Kit，與 MGI 的 DNBSEQ 測序儀兼容。 該試劑盒以極低的 RNA 輸入量展示了高性能，並且可以使用專有的 D-Plex 技術通過文庫製備來檢測各種小 RNA 轉錄本。

因此，研發和設施開發正在取得進展，預計研究目標市場將在預測期內擴大。 然而，寡核甘酸的高加工成本、缺乏熟練的專業人員以及欠發達國家的研究支持預計將在預測期內阻礙寡核甘酸合成市場的增長。

寡核甘酸合成市場趨勢

治療藥物板塊有望保持高CAGR

由於慢性病和罕見病患病率增加、藥物開發中越來越多地採用寡核甘酸以及產品發布增加等因素，預計在預測期內，治療領域的寡核甘酸合成市場將出現顯著增長。

寡核甘酸療法是一類使用反義寡核甘酸或小干擾 RNA (siRNA) 靶向 RNA 或蛋白質的療法。 寡核甘酸療法包括靶向轉錄因子以阻斷轉錄的誘餌，調節與特定 mRNA 互補的 microRNA (miRNA) 的表達，並限制特定蛋白質從 mRNA 的翻譯。 例如，根據 2022 年 2 月發表在 Future Medicine 上的一篇文章，寡核甘酸療法是創造罕見疾病治療方法的最具適應性的平台之一。

此外，成長型公司努力採用各種業務戰略，例如合作夥伴關係和融資，也有助於市場增長。 例如，2022 年 1 月，Ceptur Therapeutics, Inc. 宣布將基於其專有的 U1 接頭技術開發 RNA 療法，這是一種結合序列特異性 mRNA 和 U1 微核核糖核蛋白的二價寡核甘酸。成功籌集了 7500 萬美元的資金由 venBio Partners 和美國啟明創投領投的 A 輪融資。 U1 小核核糖核蛋白是一種控制轉錄和剪接的細胞內機器。 通過利用與 U1 snRNP 相互作用的合成寡核甘酸，可以利用該轉錄因子高度靶向和調節 mRNA。

此外，越來越多的產品發布和批准預計將增加對寡核甘酸藥物的需求，從而推動市場增長。 例如，2021 年 2 月，美國食品和藥物管理局批准 Amondis 45 (Kazimersen) 注射液用於治療 DMD 基因已確認突變的杜氏肌營養不良症 (DMD) 患者。

此外，多家公司正在開發寡核甘酸療法，預計這將增加製藥和生物技術行業的採用率，從而促進市場增長。 例如，根據 clinicaltrials.gov 的數據，截至 2022 年 7 月，TME Therapeutics 正在開發 STNM01，該藥物正在 I 期臨床試驗中進行評估，以治療無法切除的胰腺癌。 Nitto BioPharma 還在開發 ND-L02-s0201，該藥物正在特發性肺纖維化 (IPF) 的 II 期試驗中進行評估。

因此，由於企業活動增加、採用各種商業策略進行基於寡核甘酸的藥物開發和新產品發布等因素，預計該細分市場將在預測期內增長。.

預計北美將佔所研究市場的很大份額

北美預計將在預測期內主導市場。 市場增長的驅動因素包括慢性病和罕見病在人口中的患病率上升、公司研發支出的增加以及該地區主要市場參與者的存在。

根據 Cancer Facts and Figures 2022，預計 2022 年美國將診斷出超過 190 萬新癌症患者。 此外，根據Breastcancer.org公佈的2022年統計數據，2022年美國估計將有287,850例浸潤性乳腺癌新發病例和51,400例原位乳腺癌新發病例。 人口中日益增加的癌症負擔推動了對先進療法的需求，推動了對寡核甘酸療法的需求並推動了市場增長。

根據 IDF 發布的 2022 年統計數據，到 2021 年，加拿大約有 290 萬人患有糖尿病。 到 2030 年，這一數字預計將達到 320 萬，到 2045 年將達到 340 萬。 由於預計該國糖尿病患者人數將增加，因此在抗糖尿病藥物的開發中，對能夠在 RNA 和蛋白質水平上抑制致病基因表達的反義寡核甘酸的需求將增加。 預計這將在預測期內推動市場增長。

按地區增加藥物開發和增加產品發布預計將推動市場增長。 例如，2022年1月，美國食品和藥物管理局發布了一項針對雜合子家族性高膽固醇血症（HeFH）或臨床動脈粥樣硬化性心髒病（ASCVD）的新建議，需要額外降低低密度脂蛋白膽固醇（LDL-C）。獲得包涵體注射液（Leqvio）的批准)，一種創新的低增量矽烷 RNA 藥物，用於成人飲食和他汀類藥物治療。

此外，根據 clinicaltrials.gov，截至 2022 年 7 月，TME Pharma Agis 正在對微衛星穩定的轉移性胰腺癌患者進行 Olaptesed Pegol (NOX-A12) 聯合派姆單抗和納米脂質體伊立替康/5-FU。A II 期亞葉酸或吉西他濱/nab-紫杉醇的組合正在進行臨床試驗。

此外，公司增加投資以增加生產和擴大寡核甘酸藥物的設施也有助於市場增長。 例如，2021 年 3 月，Nitto Denko Corporation 將向其美國子公司 Nitto Denko Avecia Inc. 投資約 250 億日元（2.27 億美元），以提高其治療性寡核甘酸業務的製造能力。

在北美，由於癌症增加、產品發布和批准增加、企業開展臨床試驗的活動增加以及對寡核甘酸業務的投資增加等因素，市場將在預測期內增長。預計將得到推動.

寡核甘酸合成市場競爭者分析

市場是分散的，許多公司採用各種策略（例如收購、銷售合作夥伴關係和協作）在新興市場開發新技術。 從事寡核甘酸合成行業的公司也在擴大和開發他們的產品組合，這正在推動整個市場，使其成為一個競爭激烈的市場。 目前主導市場的公司包括 Agilent Technologies、Thermo Fisher Scientific、Merck KGaA、Danaher Corporation、Bio-Synthesis Inc、Eurofins Scientific、Kaneka Corporation (Eurogentec)、GenScript 和 LGC Limited (LGC Biosearch Technologies)。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 調查先決條件和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 政府對製藥和生物技術公司的投資和研發支出增加
    • 合成寡核甘酸在分子診斷和臨床應用中的用途
  • 市場製約因素
    • 寡核甘酸的高治療成本
    • 欠發達國家缺乏熟練的專業人員和研究支持
  • 行業吸引力 - 五力分析分析
    • 新進入者的威脅
    • 買家的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按產品類型
    • 合成寡核甘酸
    • 試劑
    • 設備
    • 服務
  • 通過使用
    • 調查研究
    • 診斷
    • 治療藥物
  • 最終用戶
    • 學術研究所
    • 製藥和生物技術公司
    • 醫院和診斷機構
  • 按地區細分
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Agilent Technologies
    • Thermo Fisher Scientific
    • Merck KGaA
    • Danaher Corporation
    • Bio-Synthesis Inc.
    • Eurofins Scientific
    • Kaneka Corporation（Eurogentec）
    • GenScript
    • LGC Limited（LGC Biosearch Technologies）
    • Maravai Life Sciences
    • Biogen
    • Sarepta Therapeutics, Inc.

第7章 市場機會與今後動向

簡介目錄
Product Code: 60475

The oligonucleotide synthesis market is expected to register a CAGR of 12.3% over the forecast period.

COVID-19 has impacted the growth of the oligonucleotide synthesis market. The increased demand for COVID-19 diagnostics has, in turn, increased the global demand for oligonucleotide raw materials that form the basis of molecular diagnostic products. In a study published in PLOS One in March 2022, it was observed that the oligonucleotides successfully targetted 5'-polyUs in the coronavirus genome. Also, developing therapeutic COVID-19 medicines employing essential mutational targets, such as the 5'-polyU tract, can lessen the production and spread of new SARS-CoV-2. Such research studies have impacted the demand and adoption for oligonucleotides in drug development, affecting the market growth during a pandemic.

Moreover, various companies are investing in oligonucleotide synthesis, which is expected to increase market growth over the forecast period. For instance, in September 2021, SpeeDx invested in local oligonucleotide manufacturing to reduce supply chain risk and develop a more vital sovereign capacity for critical diagnostics. Such developments are expected to increase the adoption of oligonucleotides in drug development which is anticipated to fuel the market growth over the forecast period.

Other significant factors include the increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies and the use of synthesized oligonucleotides in molecular diagnostics and clinical applications.

There are growing government initiatives for raising funds to develop various genome projects to develop advanced therapeutics to treat multiple chronic and rare diseases. This is expected to increase the demand for oligonucleotides for drug development, boosting the market growth. For instance, in September 2022, the National Institutes of Health invested more than USD 600 million to launch the next stage of its human genome project for the brain. This funding helps to devise new ways to target therapeutics and other molecules to specific brain cell populations.

Additionally, the rising company and government initiatives to boost the development of oligonucleotide-based drug products and the adoption of oligonucleotide technology in the pharmaceutical and biotechnology industry are also expected to increase market growth. For instance, in February 2021, CPI launched a project in the Medicines Manufacturing Innovation Centre to revolutionize the manufacture of oligonucleotides. The Medicines Manufacturing Innovation Centre launched a collaboration with AstraZeneca, Exactmer, Novartis, and UK Research and Innovation to develop a scalable, sustainable, and more cost-effective medicines manufacturing process for oligonucleotides: short strands of synthetic DNA or RNA. This development enhances the production capacity and viability of this exciting new class of medicines and is expected to increase market growth over the forecast period.

Furthermore, the increasing adoption of oligonucleotides in molecular diagnostics and clinical applications contributes to market growth. For instance, in February 2022, researchers at the University of Illinois Urbana developed a new miRNA point-of-care test for cancer detection. The test uses nanoparticles to capture tumor-specific microRNAs (miRNAs) in human serum. In January 2021, Diagenode launched a new small RNA-sequencing solution, D-Plex Small RNA DNBSEQ Kit, compatible with MGI's DNBSEQ sequencers. The kit incorporates unique D-Plex technology for library preparation enabling high performance with ultralow RNA inputs and providing diverse small RNA transcript detection.

Therefore, the studied market is expected to grow over the forecast period owing to the increasing research and development initiatives and the establishment of the facilities. However, the high treatment cost of oligonucleotides and the lack of skilled professionals and research support in undeveloped countries are expected to hinder the growth of the oligonucleotide synthesis market over the forecast period.

Oligonucleotide Synthesis Market Trends

Therapeutic Segment Expected to Register a High CAGR

The therapeutics segment is expected to witness significant growth in the oligonucleotide synthesis market over the forecast period owing to factors such as the increasing prevalence of chronic and rare diseases, along with the growing adoption of oligonucleotides in drug development and rising product launches.

Oligonucleotide therapeutics are classified as therapeutics that use antisense oligonucleotides or small interfering RNAs (siRNAs) to target RNA or protein. Oligonucleotide therapies include decoys that prevent transcription by concentrating on transcription factors, regulate the expression of complementary microRNA (miRNA) to specific mRNAs, and limit the translation of certain proteins from mRNA. For instance, as per an article published in Future Medicine in February 2022, oligonucleotide therapeutics is one of the most adaptable platforms for creating medications for rare diseases.

The growing company's focus on adopting various business strategies, such as collaborations, financing, and others, is also contributing to the market growth. For instance, in January 2022, Ceptur Therapeutics, Inc. successfully acquired USD 75 million in a Series-A financing round led by venBio Partners and Qiming Venture Partners USA to advance RNA therapeutics based on proprietary U1 adaptor technology, a bivalent oligonucleotide that engages sequence-specific mRNA and U1 small nuclear ribonuclear protein. The U1 small nuclear ribonuclear protein is a ubiquitous intracellular machine that regulates transcription and splicing. Utilizing synthetic oligonucleotides that interact with U1 snRNP offers the ability to co-opt the key transcriptome regulator to regulate mRNA in a highly targeted manner.

Furthermore, increasing product launches and approvals are expected to increase the demand for oligonucleotide drugs, propelling the market growth. For instance, in February 2021, the USFDA approved an Amondys 45 (casimersen) injection to treat Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene.

Moreover, various companies are developing oligonucleotide therapeutics, which are expected to increase their adoption in the pharmaceutical and biotechnology industry, bolstering the market growth. For instance, as per clinicaltrials.gov, as of July 2022, TME Therapeutics is developing STNM01, which is being evaluated in a Phase-I clinical study to treat unresectable pancreatic cancer. Also, Nitto Biopharma is developing ND-L02-s0201 under a Phase-II study and is being assessed for idiopathic pulmonary fibrosis (IPF).

Therefore, owing to the factors such as the increasing company activities in adopting various business strategies for developing oligonucleotide-based drugs and rising product launches, the studied segment is anticipated to witness growth over the forecast period.

North America Expected to Occupy a Significant Share in the Studied Market

North America is expected to dominate the market over the forecast period. The factors attributing to the market growth are the rising prevalence of chronic and rare diseases among the population, increasing R&D expenditure by the companies, and the presence of key market players in the region.

According to the Cancer Facts and Figures 2022, over 1.9 million new cancer cases are expected to be diagnosed in the United States in 2022. Also, as per 2022 statistics published by Breastcancer.org, an estimated 287,850 new cases of invasive breast cancer and 51,400 new cases of non-invasive (in situ) breast cancer are expected to be diagnosed in the United States in 2022. The growing burden of cancer among the population raises the need for advanced therapeutics, boosting the demand for oligonucleotide therapeutics and propelling the market growth.

As per the 2022 statistics published by IDF, about 2.9 million people were living with diabetes in Canada in 2021. This number is projected to reach 3.2 million and 3.4 million by 2030 and 2045, respectively. Thus, the expected increase in the diabetic population in the country raises the demand for antisense oligonucleotides in developing antidiabetic agents, as they can reduce the expression of disease-causing genes at the RNA and protein levels. This is anticipated to boost the market growth over the forecast period,

The increasing development of drugs and rising regional product launches are anticipated to fuel market growth. For instance, in January 2022, the USFDA approved inclusion injection (Leqvio), an innovative small inclisiran RNA medicine, to be used with diet and statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Furthermore, as per clinicaltrials.gov, as of July 2022, TME Pharma Agis is conducting a Phase II clinical study of Olaptesed Pegol (NOX-A12) combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Moreover, the increasing investment by the companies to boost the production of oligonucleotide drugs and facility expansion is contributing to the market growth. For instance, in March 2021, Nitto Denko Corporation revealed its plan to invest about JPY 25 billion (USD 227 million) in its United States-based subsidiary, Nitto Denko Avecia Inc., and other businesses to increase the manufacturing capacity of its therapeutic oligonucleotide business.

Therefore, owing to the factors such as the rising burden of cancer, rising product launches and approvals, growing company activities in conducting clinical trials as well, and increasing company focus on investing in oligonucleotides business are anticipated to fuel the market growth in the North America region over the forecast period.

Oligonucleotide Synthesis Market Competitor Analysis

The market is fragmented with the presence of a large number of players adopting various strategies, such as the acquisition of players in emerging markets, distribution partnerships, and collaboration for the development of novel technologies. The companies operating in the oligonucleotide synthesis industry are also expanding and developing their product portfolios, which helps drive the overall market and makes it fairly competitive. Some of the companies which are currently dominating the market are Agilent Technologies, Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, Bio-Synthesis Inc., Eurofins Scientific, Kaneka Corporation (Eurogentec), GenScript, and LGC Limited (LGC Biosearch Technologies).

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope Of The Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Government Investments and R&D Expenditure in Pharmaceutical and Biotechnology Companies
    • 4.2.2 The Use of Synthesized Oligonucleotides in Molecular Diagnostics and Clinical Applications
  • 4.3 Market Restraints
    • 4.3.1 High Treatment Cost of Oligonucleotides
    • 4.3.2 Lack of Skilled Professionals and Research Support in Undeveloped Countries
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product Type
    • 5.1.1 Synthesized Oligonucleotide Products
    • 5.1.2 Reagents
    • 5.1.3 Equipment
    • 5.1.4 Services
  • 5.2 By Application
    • 5.2.1 Research
    • 5.2.2 Diagnostics
    • 5.2.3 Therapeutics
  • 5.3 By End-user
    • 5.3.1 Academic Research Institutes
    • 5.3.2 Pharmaceutical and Biotechnology Companies
    • 5.3.3 Hospital and Diagnostic Laboratories
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 Thermo Fisher Scientific
    • 6.1.3 Merck KGaA
    • 6.1.4 Danaher Corporation
    • 6.1.5 Bio-Synthesis Inc.
    • 6.1.6 Eurofins Scientific
    • 6.1.7 Kaneka Corporation (Eurogentec)
    • 6.1.8 GenScript
    • 6.1.9 LGC Limited (LGC Biosearch Technologies)
    • 6.1.10 Maravai Life Sciences
    • 6.1.11 Biogen
    • 6.1.12 Sarepta Therapeutics, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS